Advances in Nonmetastatic Castrate-Resistant Prostate Cancer (and High-Risk Disease)

In this downloadable slideset, David F. Penson, MD, reviews the latest evidence and guidelines supporting the optimal management of patients with nonmetastatic castration-resistant prostate cancer.
David F. Penson, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.59 MB
Released: May 3, 2019

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by independent educational grants from
Astellas
Pfizer, Inc.

Related Content

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on best practices in classifying prostate cancer and using ADT

Daniel W. Lin, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with mHSPC.

Alicia K. Morgans, MD, MPH Released: September 10, 2021

Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, review key data in genitourinary cancers from the 2021 ASCO Annual Meeting, as reported by Clinical Care Options (CCO)

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 7, 2021 Expired: September 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue